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Introduction: The report of cases of lung squamous cell cancers 
harboring anaplastic lymphoma kinase (ALK) gene rearrangements 
raises the question whether this histologic subtype should be also 
evaluated for such molecular predictive test.
Methods: A consecutive series of 40 lung pure squamous cell car-
cinomas were analyzed for ALK gene status by fluorescence in situ 
hybridization. Squamous differentiation was validated using an 
immunohistochemical panel including ∆n-p63 (p40), cytokeratin 
(CK) 5/6, sex-determining region Y (SRY)-Box2 (SOX2), thyroid 
transcription factor 1, CK7, and Napsin-A.
Results: Squamous differentiation was confirmed in all tumors as 
they stained positive for ∆n-p63 and CK5/6 and negative for thyroid 
transcription factor 1 and Napsin-A. One of 40 cases (2.5%) showed 
an ALK rearrangement on fluorescence in situ hybridization analysis.
Conclusions: ALK translocation may be found in lung pure squa-
mous cell carcinomas. Our data suggest the opportunity to test ALK 
rearrangements on biopsy samples harboring squamous cell cancer 
differentiation.
Key Words: Anaplastic lymphoma kinase rearrangement, Squamous 
cell carcinoma, Break-apart fluorescence in situ hybridization, 
 Dual-color fluorescence in situ hybridization, Targeted therapy.
(J Thorac Oncol. 2014;9: 729–732)
The recent molecular testing guidelines for selection of lung cancer patients for tyrosine kinase inhibitors recommend 
to not test anaplastic lymphoma kinase (ALK) fusion genes 
in lung cancers lacking any adenocarcinoma component.1 
However, the report of cases of lung squamous cell cancers 
harboring ALK gene rearrangements2,3 has raised the question 
whether this histologic subtype should be also evaluated for 
such molecular predictive test.4 The doubt exists that these 
cases could be adenosquamous carcinomas misdiagnosed as 
squamous cell carcinomas because of either limited sampling 
of surgically removed lesions or bioptic samples that were not 
representative of the entire lesion.5,6
As the presence of ALK rearrangement might offer a 
therapeutical option for patients affected by squamous cell 
carcinoma of the lung, we sought to assess its prevalence in a 
series of 40 consecutive bona fide squamous cell lung carcino-
mas observed at our institution.
MATERIALS AND METHODS
Tissue Samples
Forty consecutive lung squamous cell carcinomas 
surgically treated at the University and Hospital Trust of 
Verona, Italy, were retrieved from the Verona lung cancer 
database. The diagnosis was based on thorough examina-
tion of the surgical specimens that were extensively sam-
pled upon the inclusion of the entire lesion in each case. 
The histotype of carcinomas was assessed by applying an 
appropriate immunohistochemical panel: ∆n-p63 (rab-
bit; Oncogene, Boston, MA), cytokeratin (CK)5/6 (XM26; 
Novocastra, Newcastle Upon Tyne, United Kingdom), CK7 
(OV-TL12/30; Biogenex, San Ramon, CA), thyroid tran-
scription factor 1 (TTF-1) (8G7G3/1; Dako, Carpinteria, 
CA), Napsin-A (TMU-A d02; Arp, Belmont, MA), and sex-
determining region Y (SRY)-Box2 (SOX2) (rabbit; Seven 
Hills Bioreagents, Cincinnati, OH).
Interphase Fluorescence In Situ 
Hybridization Analysis
ALK gene status assessment by break-apart and  
dual-fusion probes 
Interphase cytogenetic analysis was performed by fluores-
cence in situ hybridization (FISH) by using 5-μm sections 
from formalin-fixed and paraffin-embedded tissues and a 
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commercially available break-apart ALK kit (ALK Break 
Apart FISH Probe Kit; Abbott Molecular Inc., Des Plaines, 
IL) that uses two DNA probes on the ALK gene, one at the 3′ 
and one at the 5′ regions. The case harboring a rearrangement 
of the ALK gene locus using the ALK break-apart probes 
was evaluated by the ALK/echinoderm microtubule associ-
ated protein like 4 (EML4) t(2;2); inv(2) fusion probe dual-
color assay to assess whether the fusion partner of ALK was 
the EML4 gene. The slides were examined using an Olym-
pus BX61 (Olympus, Milan, Italy) with appropriate filters 
for SpectrumOrange, SpectrumGreen, and the UV filter for 
the 4′,6-diamidino-2-phenylindole (DAPI) nuclear counter-
stain. The signals were recorded with a charge-coupled de-
vice (CCD) camera (CytoVysion, Olympus) and digitalized 
by Fluo/D-SIGHT (Menarini/Visia Imaging). A total of 150 
neoplastic nuclei were assessed in at least three different ar-
eas. Nuclei harboring split signals were scored as positive for 
ALK rearrangement, whereas nuclei with a single fluorescent 
signal were scored as having a chromosome loss.
TABLE 1.  Clinico-Pathological Features of Squamous Cell 
Lung Carcinoma Patients
Sex n%
  Male 87
  Female 13
Age, yrs
  50–70 53
  >70 47
Smokers
93
Stage
  I 48
  II 40
  II 12
  IV 0
Location
  Central 72
  Periphery 28
Smokers: >5 cigarettes per day.
FIGURE 1.  Histopathological and 
immunohistochemical findings. 
Squamous cell carcinoma (hematoxy-
lin and eosin) biopsy (A) and surgical 
sample (B). All cases strongly express 
∆n-p63 (C) and cytokeratin 5/6 (D) 
and are negative for thyroid transcrip-
tion factor 1 (E) and Napsin (F).
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RESULTS
The clinico-pathological parameters of the series are 
summarized in Table 1. A thorough examination of each case 
by extensive sampling of the entire lesion confirmed the mor-
phological diagnosis of pure squamous cell carcinoma also by 
immunohistochemistry, showing a strong and diffuse ∆n-p63, 
CK5/6, SOX-2 expression. Napsin-A, TTF-1, and CK7 were 
negative in all samples (Fig. 1).
The ALK gene rearrangement had been performed by 
two independent laboratories and interpreted by three blinded 
operators (GI, MB, AC). One of the 40 cases (2.5%) harbored 
an ALK gene rearrangement (Fig. 2A); the number of neoplas-
tic nuclei harboring the ALK split pattern ranged from 20% to 
30%. The dual-fusion FISH test revealed that the EML4 gene 
was the ALK fusion partner (Fig. 2B). The ALK–EML4 fusion 
pattern was detected in more than 50% of nuclei.
DISCUSSION
Our study demonstrates that the ALK translocation may 
be found in pure squamous carcinoma of the lung. Doubts have 
been cast on reports showing ALK rearrangements in squamous 
lung cancers, as those might represent adenosquamous neo-
plasms misdiagnosed because of false squamous cell differenti-
ation, biopsy sample not representative of the entire tumor, and 
lack of use of an immunohistochemical confirmatory panel.2–4,7 
Consequently, it is common belief that the true prevalence 
of ALK translocations in pure squamous cell lung carcinoma 
approaches zero. Our study on a series of 40 consecutive cases 
diagnosed as pure squamous cell carcinoma upon extensive 
sampling of the entire surgical specimens and confirmed by the 
typical immunophenotypical positivity for ∆n-p63 and CK5/6 
and negativity for Napsin-A, TTF-1 and CK7, revealed that one 
case (2.5%) harbored an EML4–ALK fusion gene.
The patient harboring the EML4–ALK rearranged neo-
plasm was a 56-year-old white man with a smoking history. He 
was incidentally found to be affected by a central pulmonary 
mass with adenopathy. The squamous cell histology was iden-
tified in the initial biopsy and confirmed in multiple samples 
taken from the surgical whole tumor specimen. The ALK gene 
rearrangement was detected by FISH using two distinct FISH 
kits. The first one, approved by Food and Drug Administration, 
detects the ALK gene rearrangements by the recognition of a 
break in the ALK gene but does not identify the fusion partner 
gene. The second FISH kit uses one probe for ALK and one 
probe for EML4 genes and showed that EML4 gene was the 
ALK partner in our patient’s neoplasm.
One squamous cell carcinoma was included in the 
series of Kwak et al.,8 who showed that the inhibition of ALK 
in lung tumors with ALK rearrangements resulted in tumor 
shrinkage or stable disease in most patients. Other reports 
included additional single squamous cell lung cancer cases 
with ALK rearrangements (Table 2).9–12 However, the recent 
molecular testing guidelines for selection of lung cancer 
FIGURE 2.  Interphase FISH analysis. 
A break-apart dual-color ALK probes, 
where the green and red signals are 
split apart demonstrate the break of the 
ALK gene (A), and a dual-color assay 
FISH EML4 and ALK probes, where the 
dual-fusion of adjacent red and green 
signals demonstrate the EML4-ALK 
rearrangement (B). FISH, fluorescence 
in situ hybridization; ALK, anaplastic 
lymphoma kinase; EML4, echinoderm 
microtubule associated protein like 4.
TABLE 2.  Squamous Cell Carcinomas with ALK Gene Rearrangements Detected by FISH
Source, yr n Percentage Material
Rikova et al.,20079 1 n.r. n.a.
Soda et al., 200710 1 n.r. n.a.
Kwak et al., 20108 1 n.r. n.a.
Camidge et al., 201212 2 n.r. n.a.
Alrifai et al., 20132 1 Case report Biopsy
Gainor et al., 20137 3 n.r. Biopsy
Ochi et al., 20134 1 Case report Biopsy
Kim et al., 20133 1 Case report Biopsy
Seto et al., 201311 1 Case report Biopsy or resection
Present series, 2013 1 2.5% Surgical specimen
FISH, fluorescence in situ hybridization; n.a., not available; n.r., the number of squamous cell carcinomas analyzed is not reported.
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patients for tyrosine kinase inhibitors recommend not test-
ing ALK fusion genes in squamous cancers based on a meta-
analysis in which only one of 522 squamous cell carcinomas 
(0.2%) was found to harbor an ALK rearrangement.1 This 
view could find support from the study by Boland et al.13 
who reported a prevalence of ALK translocation in 0.7% (1 
of 150) squamous cell carcinoma and in 2.7% (5 of 185) 
lung adenocarcinoma, but a limitation of this study resides 
in the use of immunohistochemistry as a screening method, 
which is less sensitive than FISH. Although the small size 
of our cohort may inflate the apparent frequency of 2.5% 
found in our series, the present study supports the hypoth-
esis that ALK gene translocation may be also present in pure 
squamous cell lung carcinoma, providing a rationale for the 
extension of ALK analysis in the context of squamous cell 
carcinoma. Although recent studies suggest that erlotinib/
gefitinib might give clinical benefit also in lung carcinoma 
with squamous components harboring epidermal growth 
factor receptor mutations,14,15 it is unclear whether patients 
with squamous cell carcinomas carrying ALK translocations 
could benefit from ALK-inhibitor agents.8
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